Literature DB >> 1744168

The role of insulin-related substance in Hodgkin's disease.

T Cabrijan1, S Levanat, B Pekić, J Pavelić, R Spaventi, H Frahm, V Zjacić-Rotkvić, V Goldoni, D Vrbanec, M Misjak.   

Abstract

An insulin-related growth-promoting substance was detected in the serum of a patient with Hodgkin's disease who suffered from severe hypoglycaemia, as well as in the supernatant of homogenized spleen tissue of the same patient. Low concentrations of this substance enhanced DNA synthesis of short-term-cultured spleen tumour cells obtained from the same patient, while the addition of anti-insulin antiserum interfered with that effect. Moreover, the preincubation of this insulin-related substance with the anti-insulin antiserum abrogated its stimulatory effect on tumour cell proliferation. Both insulin and the insulin-related substance bound to patients splenocytes to a similar extent. The data suggest that the insulin-related substance, found in this particular case of Hodgkin's disease, plays a role in tumour progression by an autocrine mechanism.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1744168     DOI: 10.1007/bf01613298

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  18 in total

1.  Isolation and purification of a substance immunologically cross-reactive with insulin (SICRI) from tumor tissue.

Authors:  S Levanat; K Pavelić
Journal:  Int J Biochem       Date:  1989

2.  Binding and degradation of 125I-labelled insulin by isolated rat fat cells.

Authors:  S Gammeltoft; J Gliemann
Journal:  Biochim Biophys Acta       Date:  1973-08-17

3.  Growth self-incitement in murine melanoma B16: a phenomenological model.

Authors:  Z Bajzer; K Pavelić; S Vuk-Pavlović
Journal:  Science       Date:  1984-08-31       Impact factor: 47.728

4.  Insulin levels in Hodgkin's disease.

Authors:  K Pavelić; B Pekić; M Slijepcević; M Popović
Journal:  Br J Haematol       Date:  1980-09       Impact factor: 6.998

5.  Identification and high yield purification of insulin-like growth factors (nonsuppressible insulin-like activities and somatomedins) from human plasma by use of endogenous binding proteins.

Authors:  B H Ginsberg; C R Kahn; J Roth; K Megyesi; G Baumann
Journal:  J Clin Endocrinol Metab       Date:  1979-01       Impact factor: 5.958

6.  Aplastic carcinoma in diabetic mice: hyperglycemia-suppressed proliferation rate and insulin synthesis by tumor cells.

Authors:  K Pavelić
Journal:  J Natl Cancer Inst       Date:  1979-01       Impact factor: 13.506

7.  Modulation of in vitro growth of murine myeloid leukemia by an autologous substance immunochemically cross-reactive with insulin and antiinsulin serum.

Authors:  Z Vuk-Pavlović; K Pavelić; S Vuk-Pavlović
Journal:  Blood       Date:  1986-04       Impact factor: 22.113

8.  Autocrine tumor growth regulation and tumor-associated hypoglycemia in murine melanoma B16 in vivo.

Authors:  S Vuk-Pavlović; E C Opara; S Levanat; D Vrbanec; K Pavelić
Journal:  Cancer Res       Date:  1986-05       Impact factor: 12.701

9.  Autocrine tumour growth regulation by somatomedin C: an in-vitro model.

Authors:  K Pavelić; D Vrbanec; S Marusić; S Levanat; T Cabrijan
Journal:  J Endocrinol       Date:  1986-05       Impact factor: 4.286

10.  Correlation of substance(s) immunologically cross-reactive with insulin, glucose and growth hormone in Hodgkin lymphoma patients.

Authors:  K Pavelić; M Odavić; B Pekić; I Hrsak; S Vuk-Pavlović
Journal:  Cancer Lett       Date:  1982-10       Impact factor: 8.679

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.